Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$0.571

Market cap

$92.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$583M

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
The EPS has surged by 97% year-on-year
The net income has soared by 97% YoY
The quick ratio has declined by 30% since the previous quarter
Ironwood Pharmaceuticals's gross profit has decreased by 23% YoY and by 10% QoQ

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
161.82M
Market cap
$92.4M
Enterprise value
$583M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.29
EV/EBIT
10.08
EV/EBITDA
9.68
EV/Sales
1.84
Earnings
Revenue
$317.68M
Gross profit
$317.68M
Operating income
$53M
Net income
-$32.34M
EBIT
$57.84M
EBITDA
$60.23M
Free cash flow
$78.41M
Per share
EPS
-$0.2
EPS diluted
-$0.2
Free cash flow per share
$0.49
Book value per share
-$2.06
Revenue per share
$1.97
TBVPS
$2.02
Balance sheet
Total assets
$327.21M
Total liabilities
$661.27M
Debt
$599.08M
Equity
-$334.05M
Working capital
$112.48M
Liquidity
Debt to equity
-1.79
Current ratio
3.34
Quick ratio
3.08
Net debt/EBITDA
8.15
Margins
EBITDA margin
19%
Gross margin
100%
Net margin
-10.2%
Operating margin
16.7%
Efficiency
Return on assets
-8.8%
Return on equity
N/A
Return on invested capital
6.9%
Return on capital employed
20.7%
Return on sales
18.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-5.17%
1 week
-9.58%
1 month
-38.45%
1 year
-91.06%
YTD
-87.11%
QTD
-61.16%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$317.68M
Gross profit
$317.68M
Operating income
$53M
Net income
-$32.34M
Gross margin
100%
Net margin
-10.2%

IRWD financials

IRWD's operating margin has surged by 107% year-on-year but it is down by 37% since the previous quarter
The operating income has soared by 105% YoY but it has decreased by 43% from the previous quarter
The net income has soared by 97% YoY
IRWD's net margin has surged by 96% year-on-year

Price vs fundamentals

How does IRWD's price correlate with its fundamentals

IRWD Price vs fundamentals

IRWD Earnings waterfall

IRWD Price vs fair value

Growth

What is Ironwood Pharmaceuticals's growth rate over time

IRWD growth chart

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.29
EV/EBIT
10.08
EV/EBITDA
9.68
EV/Sales
1.84

Valuation vs average

Price to earnings (P/E)

The EPS has surged by 97% year-on-year

Price to book (P/B)

The company's equity fell by 11% QoQ

Price to sales (P/S)

IRWD's P/S is 92% below its 5-year quarterly average of 3.7 and 84% below its last 4 quarters average of 1.8
IRWD's revenue is down by 23% YoY and by 10% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
The return on sales has surged by 108% year-on-year but it has declined by 35% since the previous quarter
Ironwood Pharmaceuticals's ROIC has soared by 106% YoY but it has decreased by 42% from the previous quarter
Ironwood Pharmaceuticals's return on assets has surged by 96% YoY

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time

Assets vs liabilities

The total assets is 51% less than the total liabilities
The quick ratio has declined by 30% since the previous quarter
Ironwood Pharmaceuticals's current ratio has decreased by 29% from the previous quarter

Debt vs equity

The company's debt to equity rose by 14% YoY and by 10% QoQ
IRWD's debt is down by 13% year-on-year

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.